Guardant Health to Present New Data from its Broad Portfolio of Blood Tests at the American Association for Cancer Research Annual Meeting

Author's Avatar
Mar 09, 2022

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today it will present new data from its broad portfolio of blood tests at the American Association for Cancer Research (AACR) Annual Meeting from April 8-13, 2022. Included in the presentation will be data from its multi-cancer screening assay, next-generation Guardant SHIELD.